Webinar recording now available.
Recursion CEO Chris Gibson at our March 6 webinar explained the exciting results from Recursion’s Phase II SYCAMORE trial, the first industry-sponsored clinical trial for REC-994, a CCM drug. Watch the webinar recording on our REC-944 Updates page.
In our websinar, Dr. Gibson explained the results of the trial that were first shared on Feb. 5. Trial results include (from Recursion press release):
- REC-994 met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse events
- In comparison to placebo, treatment with REC-994 400 mg showed promising signals in both MRI-based lesion volume reduction and functional outcome as measured by changes in the modified Rankin scale (mRS) score
- In patients with cavernomas located in the brainstem, a subset of patients with significant unmet need, decreases in mean absolute total lesion volume and improvements in mRS scores with REC-994 400 mg were also observed
- Next steps will be guided by regulatory discussions and on-going long term extension study
